Clinical trial

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

NCT06145854

Study summary

ClinicalTrials.gov

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Design: OBSERVATIONAL · Status: ACTIVE NOT RECRUITING · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Cabotegravir Injection [Apretude] Normalized identity: cabotegravir Injection [Apretude] View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeOBSERVATIONAL

Start date2024-01-02

PhaseN/A

Conditions

Hivunresolved

Interventions

Cabotegravir Injection [Apretude]DRUG · verified · RxNorm: cabotegravir Injection [Apretude]

Sponsors & collaborators

Midway Specialty Care Centerlead sponsor

Mapped research locations

OrlandoFlorida, United States1 West Palm BeachFlorida, United States1 Temple TerraceFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06145854 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.